An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: Levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification

Blood

Volumn 119, Issue 2, 2012, Pages 503-512

  Stephens, Owen W ^a   Zhang, Qing ^a   Qu, Pingping ^b   Zhou, Yiming ^a   Chavan, Shweta ^a   Tian, Erming ^a   Williams, David R ^a   Epstein, Joshua ^a   Barlogie, Bart ^a   Shaughnessy, John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; INTERLEUKIN 6 RECEPTOR; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG;

AGED; ALLELE; ARTICLE; CANCER RISK; CHROMOSOME 1Q; CHROMOSOME 1Q21; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC CODE; GENOTYPE; HUMAN; INTERMEDIATE CANCER RISK; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84862909316     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-367052     Document Type: Article

References (37)

1. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005;23:1-21. (Pubitemid 40563163)
2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83-85.
3. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250(2):607-610. (Pubitemid 19171418)
4. Haura E, Livingston S, Coppola D, et al. Autocrine interleukin-6/ interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 2006;7(4):273-275. (Pubitemid 43280031)
5. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993;90(24):11924-11928. (Pubitemid 24008752)
6. Lesina M, Kurkowski M, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456-469.
7. Lust J, Donovan K, Kline M, et al. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 1992;4(2):96-100.
8. Horiuchi S, Koyanagi Y, Zhou Y, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24(8):1945-1948. (Pubitemid 24237574)
9. Jones S, Horiuchi S, Topley N, et al. The soluble Interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43-58. (Pubitemid 32061655)
10. Müllberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor: mutational characterization of the proteolytic cleavage site. J Immunol. 1994;152(10):4958-4968. (Pubitemid 24139089)
11. Galicia JC, Tai H, Komatsu Y, et al. Polymorphisms in the IL-6 receptor (IL-6r) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5(6):513-516. (Pubitemid 39263887)
12. Thabard W, Barille S, Collette M, et al. Myeloma cells release soluble interleukin-6ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. Clin Cancer Res. 1999;5:2693-2697. (Pubitemid 29493941)
13. Garbers C, Janner N, Chalaris A, et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem. 2011;286(17):14804- 14811.
14. Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet. 2007;80(4):716-726. (Pubitemid 46564408)
15. Kim L, Lee H, Kim Y, et al. Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). Hum Mut. 2003;21(4):450-451.
16. Greipp P. Prognosis in myeloma. Mayo Clin Proc. 1994;69(9):895-902. (Pubitemid 24275737)
17. Kyrtsonis M, Dedoussis G, Zervas C, et al. Soluble interleukin-6 receptor (s-IL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 1996;93(2):398-400. (Pubitemid 26150030)
18. Shaughnessy J, Zhan F, Burrington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284. (Pubitemid 46425864)
19. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monocolonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745-1757. (Pubitemid 34533050)
20. McLoughlin R, Hurst S, Nowell M, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol. 2004;172(9):5676-5683. (Pubitemid 38542071)
21. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. (Pubitemid 44395016)
22. Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 1993;23(4):820-824. (Pubitemid 23101064)
23. Hanamura I, Stewart P, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724-1732. (Pubitemid 44316143)
24. Berger R, Bernard O. Jumping translocations. Genes Chromosomes Cancer. 2007;46(8):717-723. (Pubitemid 46912342)
25. Basel-Vanagaite L, Goldberg-Stern H, Mimouni-Bloch A, et al. An emerging 1q21.1 deletion-associated neurodevelopmental phenotype. J Child Neurol. 2011;26(1):113-116.
26. Brunetti-Pierri N, Berg J, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet. 2008;40(12):1466-1471.
27. Aladzsity I, Kovacs M, Semsei A, et al. Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res. 2009;33(11):1570-1573.
28. Chesneau V, Becherer David J, Zheng Y, et al. Catalytic properties of ADAM19. J Biol Chem. 2003;278(25):22331-22340. (Pubitemid 36830282)
29. Althoff K, Reddy P, Voltz N, et al. Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem. 2000;267(9):2624- 2631. (Pubitemid 30304258)
30. Hull J, Campino S, Rowlands K, et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet. 2007;3(6):e99.
31. Zhou Y, Barlogie B, Shaughnessy J. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009;23(11):1941-1956.
32. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24(15): 2461-2473. (Pubitemid 40593037)
33. Yaccoby S, Wezeman M, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64(6):2016-2023. (Pubitemid 38339448)
34. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol. 1998;26(7):597-603. (Pubitemid 28307527)
35. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84(9):3063-3070. (Pubitemid 24328099)
36. Hata H, Xiao H, Petrucci M, et al. Interleukin-6 expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 1993;81(12):3357-3364. (Pubitemid 23172921)
37. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85(4):863-872.